Navigation Links
Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients
Date:5/17/2010

heavily treated patient population, where demonstrating benefit can be more difficult."

"I am impressed with both the strength and quality of the data from this Aeroquin trial", stated Dr. Patrick Flume, Professor of Medicine and Pediatrics at the Medical University of South Carolina and Co-Chair of the Pulmonary Guidelines Committee of the Cystic Fibrosis Foundation. "Importantly, Aeroquin represents a new class of inhaled antibiotics for the treatment of CF.  If we are to achieve our treatment objective of reducing bacterial exacerbations over the long term, it is critical that chronically infected patients be treated frequently with inhaled antibiotics.  Having multiple classes of aerosol antibiotics available will give clinicians the ability to rotate classes and tailor treatment to the needs of each individual patient.  Clinicians believe this is the best way to maximize efficacy and tolerability while minimizing resistance and side effects over the long term."

Mpex has been cleared to proceed to Phase 3 trials with Aeroquin by the U.S. FDA and is scheduled to meet with European regulatory authorities later this quarter.  Phase 3 studies are expected to begin shortly thereafter.

About Cystic Fibrosis

Patients with CF suffer from chronic infections of the lower respiratory tract that can be caused by multiple bacteria, including Pseudomonas aeruginosa. Chronic pulmonary infection is associated with a decrease in lung function over time caused by inflammation arising from bacteria and their toxins. Periodic exacerbations in the lung result from bacterial overgrowth (requiring antibacterial intervention), and these exacerbations are implicated as a major cause of morbidity and mortality in CF patients.  

'/>"/>
SOURCE Mpex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010
2. Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results
3. DUSA Pharmaceuticals Announces Slate of Nominees for Election to the Board of Directors
4. Ferring Pharmaceuticals Announces Disco Icon Gloria Gaynor as National Spokesperson for EUFLEXXA(R)
5. Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2010 First Quarter Earnings Conference Call on Monday, May 17, 2010 at 9:30 a.m. ET
6. Jazz Pharmaceuticals Announces Public Offering of Common Stock
7. China Yongxin Pharmaceuticals is Selected as one of the Qualified Pharmaceutical Distributors for Jilin Province
8. Epix Pharmaceuticals, Inc. Announces Additional Information Concerning the May 28, 2010 Auction Sale of EP-2104R MRI Imaging Agent
9. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on May 17
10. Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc.
11. Ampio Pharmaceuticals, Inc. Appoints New Chairman and Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 2014  Depomed, Inc. (NASDAQ: DEPO ) ... year 2014 financial results after the market closes on Wednesday, ... call beginning at 4:30 pm EDT, 1:30 pm PDT to discuss ... by dialing 877-317-6789 ( United States ) ... available via a live webcast on the investor relations ...
(Date:7/25/2014)... MISSION, Kan. , July 25, 2014 /PRNewswire-iReach/ ... , and TCGRx, of Powers Lake, ... exclusive partners in a distribution and co-marketing agreement ... to retail pharmacies throughout the United ... of robotics-based pharmacy management and workflow systems to ...
(Date:7/25/2014)... WOONSOCKET, R.I. , July 25, 2014  CVS ... holding a conference call on Tuesday, August 5, 2014, ... discuss its second quarter 2014 financial results. ... broadcast simultaneously through the Investor Relations portion of the ... the webcast, visit http://info.cvscaremark.com/investors . This webcast will ...
Breaking Medicine Technology:Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3
... YORK , June 21 Pfizer Inc. (NYSE: ... and Drug Administration (FDA), it will be discontinuing commercial availability of Mylotarg® ... leukemia (AML)) in the United States and that it will ... October 15, 2010 . , , ...
... , MONTEREY, Calif. , June 21 ... Cayston delivered by the Altera Nebulizer System versus tobramycin ... aeruginosa , the co-primary endpoint of non-inferiority for mean ... (FEV(1)) percent predicted after 28 days of treatment was ...
Cached Medicine Technology:Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 2Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 3Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 4Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 5Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 6PARI Pharma's Altera Delivers Gilead's Cayston in Head-to-Head Study With Tobramycin Inhalation Solution 2PARI Pharma's Altera Delivers Gilead's Cayston in Head-to-Head Study With Tobramycin Inhalation Solution 3PARI Pharma's Altera Delivers Gilead's Cayston in Head-to-Head Study With Tobramycin Inhalation Solution 4
(Date:7/27/2014)... Manufacturers of natural ingredient beauty creams are now ... younger appearance. The Cherry News company has published its ... women explore the availabilities from U.S. retailers at ... the posted guide on the Cherry News website provide ... to some natural ingredient formulas is the high sticker ...
(Date:7/27/2014)... CA (PRWEB) July 27, 2014 Ticket Down ... Tickets at The Forum in Inglewood, California on November 15th. ... and diehard fans can expect to hear songs from this amazing ... of Summer concert in Inglewood, California at The Forum will be ... starting at 10:00 a.m. today local time TicketDown.com. This popular ...
(Date:7/27/2014)... 2014 The constant expansion of companies ... demand for enterprise video. Additional factors that have increased ... areas such as corporate communication, learning and development, security ... all these factors the enterprise video market value has ... reach $35.57 billion in 2018 with a compound annual ...
(Date:7/27/2014)... The report, “Oil Filter & Fuel Filter Market by ... (OE & Aftermarket), Filter Type (Oil & Fuel), Fuel ... & Forecast to 2018”, defines and segments the global ... forecasting of the global volume and revenue. The market ... revenue of $6.1 billion in 2018, while fuel filter ...
(Date:7/27/2014)... European Bromine market report defines and segments the Bromine market ... market in European region comprises of four major countries. They ... forms a dominant share of Bromine market influences the demand ... through the TOC of the Europe Bromine Market report, to ... the TOC of the Europe Bromine Market report. The report ...
Breaking Medicine News(10 mins):Health News:Natural Eye Cream Buyer's Guide Published Online at Consumer News Website 2Health News:5 Seconds of Summer Tickets at The Forum in Inglewood (Los Angeles), CA Now Available For Sale at Ticket Down 2Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 4Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 2Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 3Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 4Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 5Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 4
... muscle, bone behind severity of damage, longer recovery, study finds ... muscles of the lower body appear to be more vulnerable ... new study suggests. , The study analyzed the weight and ... over a three-year period. Sprains, such as to the ankle ...
... ranked among the top competitors in the world for Biathlon competitions. As ... Games to be held in Vancouver, Canada. Lanny and Tracy are crediting ... helping them get the most out of their training. , ... Parsippany, ...
... from Sticky Jewelry make a difference. Sticky J attends the "Walk ... and the Juvenile Diabetes Research Foundation made the day a success. ... ... 2000 Sticky Jewelry (StickyJ.com) has specialized in selling personalized jewelry ...
... of swine flu casesBELIZE CITY, Belize, May 1 ... residents and travelers against the swine flu, which is now ... additional proactive steps towards protection against the pandemic. ... Zone and casinos in the town of Corozal, which borders ...
... SCARBOROUGH, Maine , May 1, Binax, ... diagnostic tests to identify the causative pathogens of infectious ... information has been distributed to customers and potential customers of ... of the BinaxNow(R) Influenza A & B test has not ...
... with cancer that is resistant to standard therapy is the ... obtained in some settings, in many cases the therapies have ... has now been uncovered by a team of researchers, led ... London School of Medicine and Dentistry, London. , In the ...
Cached Medicine News:Health News:Obese Children More Likely to Suffer Lower Body Injuries 2Health News:Twin Sisters Set Their Sights On Biathlon Gold At The 2010 Winter Games 2Health News:Sticky Jewelry & JDRF Team Up to Find a Cure 2Health News:Sticky Jewelry & JDRF Team Up to Find a Cure 3Health News:Belize Takes Further Action Regarding Influenza A (H1N1) to Ensure Safety of Travelers 2
... the most advanced visual electrodiagnostic system ... of retinal and optic nerve function. ... drives this powerful computer-controlled instrument. With ... pattern stimulation, rapid Ganzfeld flash rate ...
... The Universal Biomedical Amplifier (UBA-4204) ... true DC signal amplification and ... commonly seen amplifier problems of ... saturation. These features make the ...
The STALIF stand-alone anterior lumbar fusion cage is the latest product development from Surgicraft. STALIF is the natural evolution of the Hartshill Horseshoe, which has over 10 years clinical suc...
... PACHETTE 3 will enable eye care professionals ... utilizing improved ultrasound technology. The PACHETT 3 ... algorithm used in all the DGH pachymeters ... DGH Model 555 PACHETTE 3 is capable ...
Medicine Products: